| Protein Name: | Cytochrome P450 2C19 (P33261) |
|---|---|
| Gene Name: | CYP2C19 |
| Description: | |
| PDB ID: | 4GQS |
| Protein Family: | PF00067, PS00086 |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Amitriptyline | Fatal Bleeding | Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days@ the dose of the anticoagulant should be reduced by one-third to one-half@ and prothrombin times should be monitored closely A similar effect has been reported with fluindione@ an oral vitamin K antaGOnist@ when administered concomitantly with Cordarone [ ADR Type 4 ] | Nonspecific factors and side effect complaints Factors affecting the incidence of drowsiness in drug and placebo treated anxious and depressed outpatients |
| Cimetidine | Dangerous Side Effects | Cimetidine inhibits CYP2C19-mediated S-mephenytoin 4#-hydroxylation@which may increase the level of mephenytoin in blood and cause dangerous side effects [ ADR Type 4 ] | Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole |
| Diazepam | Dangerous Side Effects | Diazepam inhibits CYP2C19-mediated S-mephenytoin 4#-hydroxylation@as a result it increases the level of mephenytoin in blood and causes dangerous side effects [ ADR Type 4 ] | CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase |
| Diazepam | Sedation | Prolonged sedation [ ADR Type 1 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
| Methsuximide | Dangerous Side Effects | Methsuximide inhibits CYP2C19-mediated S-mephenytoin 4#-hydroxylation@ which may increase the level of mephenytoin in blood and cause dangerous side effects [ ADR Type 4 ] | The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides |
| Phenytoin | Hepatotoxicity | These results suggest that P450 2C19 and other forms from the 2C and 3A subfamilies may be targets as well as catalysts of drug-protein adduct formation from phenytoin [ ADR Type 2 ] | Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation |
| Phenytoin | Toxic Phenomena | TCAs inhibit both CYP2D6 and CYP2C19 and that the interaction between TCAs and phenytoin involves inhibition of CYP2C19-catalyzed phenytoin p-hydroxylation@ which inhibits phenytoin elimination@ with a consequent risk for toxic phenomena. [ ADR Type 4 ] | Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin |
| S-mephenytoin | Dangerous Side Effects | Ethosuximide inhibits CYP2C19-mediated S-mephenytoin 4#-hydroxylation@ which may increase the level of mephenytoin in blood and cause dangerous side effects. [ ADR Type 4 ] | Safety of anticonvulsants in hepatic porphyrias |
| Warfarin | Anticoagulated Blood Effects | Chlortalidone inhibits Cytochrome P450 1A2 activity@thus attenuates anticoagulated blood effects of R-warfarin [ ADR Type 4 ] | Warfarin interactions with chloral hydrate and glutethimide |
| Warfarin | Attenuate Anticoagulated Blood Effects | Glutethimide inhibits Cytochrome P450 1A2 activity@thus attenuates anticoagulated blood effects of R-warfarin [ ADR Type 4 ] | Clinical implications of warfarin interactions with five sedatives |
This panel provides information on drug category